Texas

Reata announced late Monday that the second part of its Phase II MOXIe trial met the goal of modified Friedreich’s Ataxia Rating Scale after 48 weeks of treatment.

Companies strengthen their leadership teams and boards of directors with these appointments.

It was another busy week for clinical trials. Here’s a look.

New clinical data shows that Eli Lilly’s investigational oncology drug pegilodecakin, in combination with a checkpoint inhibitor, could be a potential new treatment for patients with non-small cell lung cancer and kidney cancer.

The deal had the upside potential of $1.7 billion but showed mixed results in three Phase III clinical trials. Sanofi announced it had terminated the collaboration, but Lexicon lashed out, alleging Sanofi’s termination was “invalid” and the company was “in breach of contract.”

Do you wake up every morning dreading going to work? If this happens to you even once a week, it may be time to start looking for a new gig.

Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.

Biopharma companies strengthen their leadership and boards with these appointments.

AuroLase Therapy is a focal ablation treatment utilizing gold nanoparticles. The nanoparticles heat and destroy cancer cells.

Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.